2023-07-11 04:19:51
The Food and Drug Administration (FDA), the equivalent of theUnited States Drug Administration, has just given its authorization for the marketing of UZEDY, the treatment developed by this lab to treat this mental illness.
The Chairman of the Management Board of MedinCell, Christophe Douat, was the guest of La Nouvelle Eco this Tuesday morning.
MedinCell has developed a new treatment once morest schizophenia thanks to a molecule, Risperodine, classified as an antipsychotic. The particularity of this treatment is that it is carried out in the form of a subcutaneous injection, much less painful than an intramuscular injection, as offered by more conventional treatments.
This injection is long-acting and can last for one to two months.
According to the tests carried out before the authorization of its placing on the American market, the treatment is effective from the 1st injection and the risk of relapse would thus be reduced by 80%. However, itEach relapse is synonymous with several weeks or months of hospitalization. In the United States, the schizophenia treatment market is worth more than 4 billion dollars, and the company MedinCell should receive between 5 and 10% of all UZEDY sales.
But paradoxically, if it is going to be made available to American patients, this medicine is not yet available in France, or the disease affects approximately 600,000 people (compared to 3.5 million in the United States).
The decision to place it on the French market actually belongs to the TEVA group, the pharmaceutical giant, with which MedinCell has partnered in the development of this new treatment.
MedinCell, a publicly traded company, currently employs over 140 people representing more than 25 different nationalities.
1689049517
#MedinCell #Jacou #lab #attacking #American #market
